- Home
- NRT vs IGC Comparison
NRT vs IGC Comparison
Compare NRT & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRT | IGC |
|---|---|---|
| Founded | 1975 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.0M | 32.0M |
| IPO Year | 1995 | 2005 |
Fundamental Metrics
Financial Performance| Metric | NRT | IGC |
|---|---|---|
| Price | $8.63 | $0.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.25 |
| AVG Volume (30 Days) | 28.1K | ★ 505.2K |
| Earning Date | 05-29-2026 | 03-19-2026 |
| Dividend Yield | ★ 10.18% | N/A |
| EPS Growth | N/A | ★ 59.09 |
| EPS | ★ 0.70 | N/A |
| Revenue | N/A | ★ $1,271,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $13.06 |
| P/E Ratio | $12.29 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.23 | $0.24 |
| 52 Week High | $10.49 | $0.45 |
Technical Indicators
Market Signals| Indicator | NRT | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 43.46 | 52.14 |
| Support Level | $8.48 | $0.27 |
| Resistance Level | $9.52 | $0.31 |
| Average True Range (ATR) | 0.24 | 0.01 |
| MACD | -0.07 | 0.00 |
| Stochastic Oscillator | 12.22 | 64.85 |
Price Performance
Historical ComparisonAbout NRT North European Oil Royality Trust
North European Oil Royalty Trust holds overriding royalty rights covering gas and oil production in certain concessions or leases in the Federal Republic of Germany. The properties of the trust are overriding royalty rights on sales of gas, sulfur, and oil under certain concessions or leases in the Federal Republic of Germany. The trust also holds other royalty rights, which are based on leases. It receives various percentages of royalties on the proceeds of the sales of certain products from the areas involved.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.